Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis

References

• American Optometric AssociationCare of the patient with conjunctivitisOptometric clinical practice guideline http://www.aoa.org/documents/CPG-11.pdfAccessed September 22, 2009
   Google Scholar
• BrookIOcular infections due to anaerobic bacteria in childrenJ Pediatr Ophthalmol Strabismus2008452788418404954
   PubMed Web of Science ®Google Scholar
• TarabishyABJengBHBacterial conjunctivitis: a review for internistsCleve Clin J Med200875750751218646586
   PubMed Web of Science ®Google Scholar
• HussarDANew drugs: golimumab, besifloxacin hydrochloride, and artemether/lumefantrineJ Am Pharm Assoc (2003)200949457057419589772
   PubMed Web of Science ®Google Scholar
• CavuotoKZutshiDKarpCLMillerDFeuerWUpdate on bacterial conjunctivitis in South FloridaOphthalmology20081151515617572497
   PubMed Web of Science ®Google Scholar
• SheikhAHurwitzBAntibiotics versus placebo for acute bacterial conjunctivitisCochrane Database Syst Rev20062CD00121116625540
   PubMedGoogle Scholar
• AsbellPAColbyKADengSOcular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolatesAm J Ophthalmol2008145695195818374299
   PubMed Web of Science ®Google Scholar
• MorrowGLAbbottRLConjunctivitisAm Fam Physician19985747357469490996
   PubMed Web of Science ®Google Scholar
• DiamantJIHwangDGTherapy for bacterial conjunctivitisOphthalmol Clin North Am19991211520
   Google Scholar
• ArnoldDRGranvilCPWardKWProkschJWQuantitative determination of besifloxacin, a novel fluoroquinolone antimicrobial agent, in human tears by liquid chromatography-tandem mass spectrometryJ Chromatogr B Analyt Technol Biomed Life Sci20088671105110
   PubMed Web of Science ®Google Scholar
• DalhoffAShalitIImmunomodulatory effects of quinolonesLancet Infect Dis20033635937112781508
   PubMed Web of Science ®Google Scholar
• CambauEMatratSPanXSTarget specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coliJ Antimicrob Chemother200963344345019147516
   PubMed Web of Science ®Google Scholar
• AsbellPASahmDFShawMDraghiDCBrownNPIncreasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005J Cataract Refract Surg200834581481818471638
   PubMed Web of Science ®Google Scholar
• GoldsteinMHKowalskiRPGordonYJEmerging fluoroquinolone resistance in bacterial keratitis: a 5-year reviewOphthalmology199910671313131810406613
   PubMed Web of Science ®Google Scholar
• Besivance [package insert]Tampa, FLBausch and Lomb Inc2009
   Google Scholar
• ProtzkoEBowmanLAbelsonMPhase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitisInvest Ophthalmol Vis Sci20074883425342917652708
   PubMed Web of Science ®Google Scholar
• McDonnellGRussellADAntiseptics and disinfectants: activity, action, and resistanceClin Microbiol Rev19991211471799880479
   PubMed Web of Science ®Google Scholar
• BlondeauJMBorsosSHesjeCKAntimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureusJ Chemother200719214615117434822
   PubMed Web of Science ®Google Scholar
• ProkschJWGranvilCPSiou-MermetRComstockTLPaternoMRWardKWOcular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humansJ Ocul Pharmacol Ther200925433534419492955
   PubMed Web of Science ®Google Scholar
• WardKWLepageJFDriotJYNonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic useJ Ocul Pharmacol Ther200723324325617593008
   PubMed Web of Science ®Google Scholar
• HaasWPillarCMZurenkoGELeeJCBrunnerLSMorrisTWBesifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteriaAntimicrob Agents Chemother20095383552356019506065
   PubMed Web of Science ®Google Scholar
• HwangDGFluoroquinolone resistance in ophthalmology and the potential role for new ophthalmic fluoroquinolonesSurv Ophthalmol200449Suppl 2S79S7815028483
   PubMed Web of Science ®Google Scholar
• TepedinoMEHellerWHUsnerDWPhase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitisCurr Med Res Opin20092531159116919323612
   PubMed Web of Science ®Google Scholar
• KarpeckiPDepaolisMHunterJABesifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety studyClin Ther200931351452619393842
   PubMed Web of Science ®Google Scholar
• McDonaldMBProtzkoEEBrunnerLSEfficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitisOphthalmology2009116916151623e119643483
   PubMed Web of Science ®Google Scholar
• Data on fileBausch and LombRochester, NY
   Google Scholar
• PaternoMRComstockTLLynchJAUsnerDWBesifloxacin ophthalmic suspension 0.6% is safe and well tolerated in patients with bacterial conjunctivitisInvest Ophthalmol Vis Sci200950 E-Abstract 2674
   Google Scholar
• ComstockTLPaternoMRLynchJADeCoryHHUsnerDWEfficacy and safety of besifloxacin ophthalmic suspension 0.6% in pediatric patients with bacterial conjunctivitisOptometry200980629629720362128
   PubMedGoogle Scholar
• ZhangJZKrenzerKLLópezFJWardKWComparative effects of besifloxacin and other fluoroquinolones on corneal reepitheliazation in the rabbitPresented at: 5th International Conference on Ocular InfectionsFebruary 18–21, 2010Palm Beach, FL
   Google Scholar
• ClaxtonAJCramerJPierceCA systematic review of the associations between dose regimens and medication complianceClin Ther20012381296131011558866
   PubMed Web of Science ®Google Scholar